Acute Myeloid Leukemia
Conditions
Keywords
Palliative Care
Brief summary
AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity therapies that have improved outcomes for older AML patients, AML remains associated with poor prognosis as well as high symptom burden. While the benefits of early palliative care as well as electronic PROs have been well-described in the oncology population, neither have been well-studied in the AML population, and have never been studied in combination. We propose a prospective, single-center, single-arm trial to evaluate the feasibility of a virtually-mediated supportive care model utilizing both electronic PROs and palliative care for patients with AML being treated with low-intensity therapy. AIM1: is to evaluate and describe the feasibility of implementing early specialty palliative care referrals carried out via telehealth/video-based modalities in combination with digital symptom monitoring for patients recently diagnosed with acute myeloid leukemia (AML) and starting low intensity induction therapy. AIM2: study the differences in health-related quality-of-life (HRQoL) metrics using patient-reported outcomes (PROs) in patients recently diagnosed with AML and starting low intensity induction therapy who receive early referral to telehealth/video-based palliative care visits compared to standard care. AIM3: to explore the patient experience of patients with AML on low-intensity therapy, capture rates of advance care planning, hospice utilization, and hospital utilization.
Interventions
OTHERPalliative Care + Digital Symptom Monitoring
Previously described in Arm description
Sponsors
Varian Medical Systems
Stanford University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients being treated for a diagnosis of acute myeloid leukemia at Stanford Cancer Center * Patients determined to be candidates for low intensity induction therapy (not requiring hospitalization to administer treatment) by their leukemia physician * Estimated life expectancy of 6 months * Functional status at the level of at least being capable of limited self-care, confined to chair or bed for half the day or better * Access to smartphone, tablet, or computer with capability to utilize a symptom tracking application
Exclusion criteria
* Relapsed or refractory AML * Patients who have established care with palliative care previously * Non-English-speaking, as the Noona application is developed in the English language
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of completed palliative care referrals and monthly visits | Through study completion, an average of 6 months | This will be measured as a percentage of patients who overall complete the initial palliative care referral and at least 50% of their scheduled monthly visits |
| Rate of usage of digital symptom monitoring application, Noona | Through study completion, an average of 6 months | This will be measured by the percentage of patients who complete at least 50% of Noona surveys associated with their palliative care visits |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in Patient Health Questionnaire (PHQ)-9 scores | Baseline, 3 months, and 6 months | Minimum score 0, maximum score 27, with higher scores indicating worse mood |
| Mean change in Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) scores | Baseline, 3 months, and 6 months | Health-related quality of life instrument used in patients with acute myeloid leukemia, minimum score 0, maximum score 176, higher scores indicating worse quality of life |
| Overall satisfaction with usage of Noona questionnaire | Baseline, 6 months | Measured qualitatively, by whether patients strongly agree, somewhat agree, are neutral, somewhat disagree, or strongly disagree with statements regarding the Noona instrument |
| Mean change in Satisfaction with Decision-Making Scale scores | Baseline, 3 months, and 6 months | Minimum score 6, maximum score 25, with higher scores indicating improved satisfaction |
| Mean change in Hospital Anxiety and Depression Scale (HADS) scores | Baseline, 3 months, and 6 months | Hospital Anxiety and Depression survey used to measure anxiety and depression, minimum score 0, maximum score 42, with higher scores indicating increased anxiety/depression |
Countries
United States
Outcome results
None listed